# US 12,758,581 B2 · Use of plasma and plasma fractions for improvement of pain, wound healing, and postoperative recovery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 12,758,581 B2
- Document ID: US12758581B2
- Status: Granted
- Kind: B2
- Application number: 18/199,652
- Filed: 2023-05-19
- Published: 2023-09-14
- Granted: 2026-10-13
- Earliest claimed: 2018-10-26
- Assignees: Alkahest, Inc.
- Applicants: Alkahest, Inc.
- Inventors: Marian Castro; Ian Gallager; Viktoria Kheifets
- Web page: https://patentgrep.com/patent/US12758581B2

## CPC

- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 38/38: Albumins
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Methods and compositions for improving postoperative recovery are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing conditions associated with postoperative recovery.

## Claims

### Claim 1

A method of treating a subject for peripheral neuropathy, the method comprising administering an effective amount of a Plasma Fraction to the subject.

### Claim 2 (depends on 1)

The method of claim 1 wherein the Plasma Fraction is a Plasma Protein Fraction.

### Claim 3 (depends on 2)

The method of claim 2 wherein the Plasma Protein Fraction comprises between 83% to 95% albumin.

### Claim 4 (depends on 3)

The method of claim 3 wherein the Plasma Protein Fraction is a commercially available Plasma Protein Fraction.

### Claim 5 (depends on 1)

The method of claim 1 wherein the Plasma Fraction is a HAS.

### Claim 6 (depends on 5)

The method of claim 5 wherein the HAS is commercially available HAS.

### Claim 7 (depends on 1)

The method of claim 1 wherein the administering is performed using a Pulse Dose dosing regimen.

### Claim 8 (depends on 1)

The method of claim 1 wherein the peripheral neuropathy comprises peripheral neuropathy associated with post-operative recovery.

### Claim 9 (depends on 1)

The method according to claim 1 wherein the peripheral neuropathy is associated with carpal tunnel syndrome.

### Claim 10 (depends on 1)

The method according to claim 1 wherein the peripheral neuropathy comprises chemotherapy-induced peripheral neuropathy.

### Claim 11 (depends on 1)

The method according to claim 1 wherein the peripheral neuropathy is associated with compression and trauma.

### Claim 12 (depends on 1)

The method according to claim 1 wherein the peripheral neuropathy comprises diabetic neuropathy.

### Claim 13 (depends on 1)

The method according to claim 1 wherein the peripheral neuropathy is associated with shingles.

### Claim 14

A method of treating a subject for chemotherapy-induced peripheral neuropathy, the method comprising administering an effective amount of a Plasma Fraction to the subject.

### Claim 15 (depends on 14)

The method of claim 14 wherein the Plasma Fraction is a Plasma Protein Fraction.

### Claim 16 (depends on 15)

The method of claim 15 wherein the Plasma Protein Fraction comprises between 83% to 95% albumin.

### Claim 17 (depends on 16)

The method of claim 16 wherein the Plasma Protein Fraction is a commercially available Plasma Protein Fraction.

### Claim 18 (depends on 14)

The method of claim 14 wherein the Plasma Fraction is a HAS.

### Claim 19 (depends on 18)

The method of claim 18 wherein the HAS is commercially available HAS.

### Claim 20 (depends on 14)

The method of claim 14 wherein the administering is performed using a Pulse Dose dosing regimen.